Breaking News Instant updates and real-time market news.

PBH

Prestige Brands

, PFE

Pfizer

09:33
10/12/17
10/12
09:33
10/12/17
09:33

Pfizer announcement creates M&A opportunity for Prestige Brands,says DA Davidson

DA Davidson analyst Linda Bolton Weiser says Pfizer's (PFE) announcement that is is reviewing strategic alternatives for its $3.4B OTC drug business could create M&A opportunity down the road for Prestige Brands (PBH). If sold, the price tag could be over $10B, clearly too big for Prestige Brands, but the buyer could later sell some or all of the small brands, the analyst contended. With Prestige Brands continuing to de-lever its balance sheet and approaching the one year anniversary in January of its last deal, Weiser believes the company could within months announce an accretive acquisition. She reiterates a Buy rating and $79 price target on Prestige Brands shares.

PBH

Prestige Brands

PFE

Pfizer

  • 15

    Oct

  • 17

    Oct

  • 18

    Oct

  • 20

    Oct

  • 23

    Oct

  • 31

    Oct

  • 02

    Nov

  • 07

    Nov

  • 08

    Nov

PBH Prestige Brands

05/12/17
DADA
05/12/17
NO CHANGE
DADA
Prestige Brands should be bought on weakness, says DA Davidson
After Prestige Brands reported slightly lower than expected EPS, DA Davidson analyst Linda Bolton Weiser recommends buying the shares on weakness. The analyst says that the company's guidance for a 2%-2.5% increase in its pro forma fiscal 2018 organic sales is positive. She keeps a $79 price target and a Buy rating on the shares.
05/22/17
RAJA
05/22/17
UPGRADE
RAJA
Outperform
Prestige Brands upgraded to Outperform from Market Perform at Raymond James
05/22/17
05/22/17
UPGRADE
Target $55

Outperform
Prestige Brands upgraded to Outperform on pullback at Raymond James
As previously reported, Raymond James upgraded Prestige Brands to Outperform from Market Perform and established a $55 price target. Analyst Joseph Altobello said, over the past 18 months, the product portfolio has improved through M&A, resulting in greater scale and growth, and the pullback in shares has created an attractive entry point.
06/02/17
JEFF
06/02/17
UPGRADE
Target $54
JEFF
Hold
Prestige Brands upgraded to Hold from Underperform at Jefferies
Jefferies analyst Stephanie Wissink upgraded Prestige Brands to Hold after assuming coverage of the name. The analyst favors the company's shift toward higher growth over-the-counter products and daily use areas. She raised her price target for the shares to $54 from $45.
PFE Pfizer

09/20/17
09/20/17
UPGRADE
Target $39

Overweight
Pfizer upgraded to Overweight on underappreciated Ibrance at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Pfizer to Overweight from Equal Weight, stating that he believes investors underappreciate the global prospects for breast cancer drug Ibrance, which he expects to maintain its first-to-market advantage. Additionally, he views the stock's valuation as attractive relative to comps and history following a long period of "middling" performance. Risinger raised his price target Pfizer shares to $39 from $35.
09/20/17
09/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he believes investors underappreciate the global prospects for breast cancer drug Ibrance, which he expects to maintain its first-to-market advantage. 2. Progressive (PGR) upgraded to Neutral from Underperform at Credit Suisse with analyst Ryan Tunis citing the announcement of much lower than expected Harvey losses of approximately $230M versus his estimate of $550M. 3. American Airlines (AAL) and Southwest (LUV) were upgraded to Outperform from Market Perform at Raymond James. 4. Post Holdings (POST) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he expects the company to be boosted by egg price increases. 5. Nordson (NDSN) upgraded to Buy from Neutral at Longbow with analyst Christopher Dankert saying ATS growth concerns are overblown and views valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
10/11/17
DBAB
10/11/17
NO CHANGE
Target $38
DBAB
Buy
Pfizer sale of consumer unit most likely option, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert believes a sale of Pfizer's Consumer Healthcare unit is the most likely outcome of the company's strategic review process. The analyst says he wouldn't be surprised if Pfizer has already received indications of interest in the business. A sale of the unit could be 3%-4% accretive depending on the price and assuming the company uses the proceeds to repurchase shares in order to offset dilution, Gilbert tells investors in a research note. He likes that management continues to explore strategic alternatives to increase shareholder value and keeps a Buy rating on Pfizer with a $38 price target.

TODAY'S FREE FLY STORIES

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

ADOM

Adomani

$6.50

-0.36 (-5.25%)

17:21
10/16/17
10/16
17:21
10/16/17
17:21
Syndicate
Breaking Syndicate news story on Adomani »

Adomani files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

17:20
10/16/17
10/16
17:20
10/16/17
17:20
Hot Stocks
Spirit Airlines raises Q3 total RASM view to (6.5%) from (8.5%)-(7%) »

Sees Q3 ASMs up 18%. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$4.38

-0.08 (-1.79%)

17:16
10/16/17
10/16
17:16
10/16/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Resonant »

Longboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.85

-0.3 (-2.47%)

17:14
10/16/17
10/16
17:14
10/16/17
17:14
Hot Stocks
Breaking Hot Stocks news story on Caesars »

TPG Group reports 14.3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

IPSEY

Ipsen

$35.23

1.2 (3.53%)

, EXEL

Exelixis

$29.02

4.26 (17.21%)

17:08
10/16/17
10/16
17:08
10/16/17
17:08
Hot Stocks
Ipsen says Phase 3 Celestial trial of cabozanitinib met primary endpoint of OS »

Before the market opened,…

IPSEY

Ipsen

$35.23

1.2 (3.53%)

EXEL

Exelixis

$29.02

4.26 (17.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 06

    Nov

GOGL

Golden Ocean

$8.50

0.02 (0.24%)

17:06
10/16/17
10/16
17:06
10/16/17
17:06
Syndicate
Golden Ocean files to sell $66M of common stock »

DNB Markets, Arctic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSQ

Townsquare Media

$10.42

0.27 (2.66%)

17:03
10/16/17
10/16
17:03
10/16/17
17:03
Hot Stocks
Townsquare Media appoints Bill Wilson and Dhruv Prasad as co-CEOs »

Townsquare Media has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPX

WPX Energy

$10.90

0.16 (1.49%)

17:03
10/16/17
10/16
17:03
10/16/17
17:03
Initiation
WPX Energy initiated  »

WPX Energy initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

TRQ

Turquoise Hill

$3.36

0.02 (0.60%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Hot Stocks
Turquoise Hill sees FY17 Oyu Tolgoi copper production 130K-160K tonnes »

Oyu Tolgoi is expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGN

Energen

$53.18

0.3 (0.57%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Initiation
Energen initiated  »

Energen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRQ

Turquoise Hill

$3.36

0.02 (0.60%)

17:02
10/16/17
10/16
17:02
10/16/17
17:02
Hot Stocks
Turquoise Hill reports Q3 Oyu Tolgoi material mined up 9% y/y »

In 3Q17, material mined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHL

Aspen Insurance

$41.40

-0.35 (-0.84%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Hot Stocks
Aspen Insurance reports preliminary pre-tax hurricane impact of $310M »

Aspen Insurance reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

JAG

Jagged Peak Energy

$13.95

0.03 (0.22%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Initiation
Jagged Peak Energy initiated  »

Jagged Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$992.00

2.32 (0.23%)

17:00
10/16/17
10/16
17:00
10/16/17
17:00
Hot Stocks
Google expands safeguards to unwanted software infections »

Google in a posting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

  • 26

    Oct

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.